Nuvectis Pharma

Update in progress

NVCT (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for serious oncology conditions with unmet medical need. Its lead candidate, NXP900, is a small molecule in Phase 1b that inhibits the c-Src and YES1 kinases to target solid tumors. The company, formerly Centry Pharma, changed its name in July 2021. It was incorporated in 2020 and is based in Fort Lee, New Jersey.

Company score

Sentiment: 0.00; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.11; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.01; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive